跳至主要内容
临床试验/NCT06987552
NCT06987552招募中不适用

A Pilot Study of Single-Port Robot-Assisted Surgery Using Da Vinci SP Surgical System for Patients With Upper Tract Urothelial Cancer

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2024年12月24日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
25
试验地点
1
主要终点
Incidence of conversion rate

研究概览

简要总结

To evaluate patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery

详细描述

To evaluate safety, surgical outcomes, patient characteristics, and patient-reported outcomes of radical nephroureterectomy using single-port robotic surgery

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 20 years or more
  • Histologically or cytologically diagnosed upper tract urothelial cancer
  • Fitting indications of radical nephroureterectomy and ipsilateral bladder cuff resection, and deemed feasible for robotic surgery
  • ASA physical status classification 1-2 and adequate organ function
  • Patients willing and able to comply with study protocol requirements and follow-up
  • With informed consent

排除标准

  • Synchronous bladder cancer
  • Distant metastasis of cancer
  • BMI ≥30 or BMI <18.5
  • Unable to tolerate lateral decubitus or Trendelenburg position (relative contra-indication)
  • Severe adhesion due to prior abdominopelvic surgery (relative contra-indication)
  • Previous radiation treatment to the pelvic area
  • Active infectious disease
  • Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic interventions, such as: severe heart disease (NYHA functional class III-IV) or severe lung disease (GOLD Group C-D)
  • Cannot follow trial-required procedures
  • Concomitant systemic or pelvic disease that increases the risk of surgery
  • Long-term use of anti-coagulant(s)
  • Patients with coagulopathy
  • Emergency surgery

结局指标

主要结局

Incidence of conversion rate

时间窗: During Surgery

The primary performance endpoint will be assessed as the ability to successfully completed the planned procedure with da Vinci SP System, with no conversion to alternative surgery including open surgery or laparoscopy.

次要结局

  • Perioperative Parameters: Operative Time(immediately after the surgery)
  • Perioperative Parameters: Console Time(immediately after the surgery)
  • Perioperative Parameters: Transfusion(immediately after the surgery)
  • Perioperative Parameters: Estimated Blood Loss(immediately after the surgery)
  • Postoperative Parameters: Length of Stay(30 days post operation)
  • Complication(30 days post operation)
  • Postoperative Parameters: Readmission(30 days post operation)
  • Postoperative Parameters: Reoperation(30 days post operation)
  • Perioperative Mortality(30 days post operation)
  • Pain Score(30 days post operation)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验